Libertyville, IL, United States of America

Megumi Kawai

This inventor holds 25 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Angiogenesis Inhibitors. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., Other. Active years: 1993-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Megumi Kawai. Retrieved from https://idiyas.com/inventor/megumi-kawai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 2)

% Patents Active = 84.0

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 419(Granted Patents)

Location History:

Liverty Ville, IL (US) (1995)
Libertyville, IL (US) (1993 - 2015)

Company Filing History:

23 out of 4,188

Abbott Laboratories Corporation

1 out of 834,513

Other

patents

Years Active: 1993-2015

Loading Chart...

Areas of Expertise:

Imidazopyridines

Pyrazolo[3,4-d]pyrimidines

Protein Kinase Inhibitors

Antiangiogenic Drug

3-Amino-2-hydroxyalkanoic Acids

Hydrazide Inhibitors

Macrocyclic Immunomodulators

Substituted Amines

Heterocycles

Anaphylatoxin-Receptor Ligands

Hexapeptides

Peptide Ligands

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9051315 - Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition (2015-06-09),

2. 7772231 - Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors (2010-08-10),

3. 7491718 - Sulfonamides having antiangiogenic and anticancer activity (2009-02-17),

4. 7030262 - 3-Amino-2-hydroxyalkanoic acids and their prodrugs (2006-04-18),

5. 6887863 - Hydrazide and alkoxyamide angiogenesis inhibitors (2005-05-03),

6. 6849757 - Antiangiogenic drug to treat cancer, arthritis and retinopathy (2005-02-01),

7. 6632961 - Antiangiogenic drug to treat cancer, arthritis and retinopathy (2003-10-14),

8. 6323228 - 3-substituted indole angiogenesis inhibitors (2001-11-27),

9. 6242494 - Substituted &bgr;-amino acid inhibitors of methionine aminopeptidase-2 (2001-06-05),

10. 6121257 - Sulfamate containing macrocyclic immunomodulators (2000-09-19),

11. 5708002 - Macrocyclic immunomodulators (1998-01-13),

12. 5604294 - Macrocyclic immunomodulators (1997-02-18),

13. 5561228 - Macrocyclic immunomodulators (1996-10-01),

14. 5561140 - Substituted alicyclic amine-containing macrocyclic immunomodulators (1996-10-01),

15. 5561139 - Substituted alicyclic-aliphatic amine-containing macrocyclic (1996-10-01),

Title: Megumi Kawai: Pioneering Innovations in Kinase Inhibition

Introduction: Megumi Kawai, based in Libertyville, IL, is a distinguished inventor recognized for his significant contributions to the field of medicinal chemistry and biotechnology. With an impressive portfolio of 25 patents, Kawai has made notable advancements in the development of compounds targeting protein kinases, which play crucial roles in various diseases.

Latest Patents: Among his latest innovations, Kawai has developed novel compounds such as imidazopyridines designed for multi-targeted kinase inhibition. These compounds not only include methods for treating diseases but also offer various compositions containing the active ingredients. Another significant patent granted to Kawai involves substituted pyrazolo[3,4-d]pyrimidines, which are recognized for their ability to inhibit protein kinases, thus enhancing treatment options for various conditions.

Career Highlights: Kawai's career includes working at renowned institutions like Abbott Laboratories Corporation, where he expanded his research and development expertise. His tenure at such a prestigious company reflects his dedication to advancing pharmaceutical innovations that have the potential to improve patient outcomes globally.

Collaborations: Throughout his career, Megumi Kawai has collaborated with prominent scientists in the field, including Jay R. Luly and Yat Sun Or. These partnerships have facilitated the exchange of ideas and fostered breakthroughs in the development of effective therapeutic compounds.

Conclusion: Megumi Kawai stands out as an influential inventor whose innovations in kinase inhibition are paving the way for new treatment avenues. With a robust portfolio of patents and collaborative efforts with leading professionals, Kawai continues to impact the pharmaceutical landscape significantly. His work exemplifies the important intersection of scientific research and practical applications in healthcare.

Profile summary based on public USPTO records.